A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Regenxbio Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 11,841 shares of RGNX stock, worth $129,066. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,841
Previous 10,540 12.34%
Holding current value
$129,066
Previous $189,000 31.75%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 25, 2024

BUY
$12.17 - $24.61 $15,833 - $32,017
1,301 Added 12.34%
11,841 $249,000
Q3 2023

Oct 25, 2023

BUY
$16.46 - $19.99 $55,618 - $67,546
3,379 Added 47.19%
10,540 $173,000
Q2 2023

Aug 07, 2023

BUY
$17.23 - $21.71 $33,632 - $42,377
1,952 Added 37.47%
7,161 $143,000
Q4 2022

Feb 01, 2023

BUY
$20.4 - $24.73 $22,358 - $27,104
1,096 Added 26.65%
5,209 $118,000
Q1 2022

Apr 21, 2022

SELL
$24.62 - $34.31 $29,790 - $41,515
-1,210 Reduced 22.73%
4,113 $137,000
Q4 2021

Feb 01, 2022

SELL
$30.19 - $40.28 $2,294 - $3,061
-76 Reduced 1.41%
5,323 $174,000
Q3 2021

Nov 15, 2021

SELL
$29.09 - $45.68 $174 - $274
-6 Reduced 0.11%
5,399 $226,000
Q2 2021

Jul 30, 2021

BUY
$32.46 - $40.48 $2,207 - $2,752
68 Added 1.27%
5,405 $210,000
Q1 2021

May 03, 2021

BUY
$33.61 - $49.95 $41,138 - $61,138
1,224 Added 29.76%
5,337 $182,000
Q4 2020

Jan 28, 2021

BUY
$26.52 - $49.35 $29,490 - $54,877
1,112 Added 37.05%
4,113 $187,000
Q1 2020

May 06, 2020

BUY
$21.5 - $54.2 $24,252 - $61,137
1,128 Added 60.22%
3,001 $97,000
Q1 2019

Apr 29, 2019

SELL
$40.82 - $62.45 $14,858 - $22,731
-364 Reduced 16.27%
1,873 $107,000
Q1 2018

May 03, 2018

BUY
$24.05 - $37.5 $29,196 - $45,525
1,214 Added 118.67%
2,237 $67,000
Q4 2017

Jan 31, 2018

BUY
$26.0 - $34.6 $26,598 - $35,395
1,023
1,023 $34,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $471M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.